Cargando…

Design and rationale for the Japanese Registry of Rivaroxaban Effectiveness & Safety for the Prevention of Recurrence in Patients with Deep Vein Thrombosis and Pulmonary Embolism (J’xactly) study

INTRODUCTION: Rivaroxaban, a factor Xa inhibitor used as a direct oral anticoagulant, is beneficial over warfarin in terms of food–drug interactions and the need for therapeutic monitoring in patients with acute venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism. Bec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Okumura, Yasuo, Fukuda, Ikuo, Nakamura, Mashio, Yamada, Norikazu, Takayama, Morimasa, Maeda, Hideaki, Yamashita, Takeshi, Ikeda, Takanori, Mo, Makoto, Yamazaki, Tsutomu, Hirayama, Atsushi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2018
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6020936/ https://www.ncbi.nlm.nih.gov/pubmed/29934383 http://dx.doi.org/10.1136/bmjopen-2017-020286

Ejemplares similares

Rivaroxaban treatment for asymptomatic venous thromboembolism: insights from the J’xactly study
por: Migita, Shohei, et al.
Publicado: (2023)

Duration of Initial Intensive Rivaroxaban Therapy for Patients With Venous Thromboembolism　― Subanalysis of the J’xactly Study ―
por: Nakamura, Mashio, et al.
Publicado: (2023)

Rivaroxaban Treatment for Patients With Unprovoked or Provoked Venous Thromboembolism　― Subanalysis of the J’xactly Study ―
por: Hisatake, Shinji, et al.
Publicado: (2022)

Prognostication of Patients with Pulmonary Thromboembolism with and without Residual Deep Vein Thrombosis: A Subanalysis of the J’xactly Study
por: Yamada, Norikazu, et al.
Publicado: (2023)

Clinical Outcome After Discontinuation of Anticoagulation Therapy in Japanese Patients With Venous Thromboembolism　― Insights From the J’xactly Study ―
por: Yamashita, Takeshi, et al.
Publicado: (2022)

Relationship between baseline D-dimer and prognosis in Japanese patients with venous thromboembolism: Insights from the J’xactly study
por: Migita, Shohei, et al.
Publicado: (2023)

Design and Baseline Data for a Prospective Observational Study of Rivaroxaban in Patients with Venous Thromboembolism in Japan (XASSENT)
por: Fukuda, Ikuo, et al.
Publicado: (2021)

Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism – the J-EINSTEIN DVT and PE program
por: Yamada, Norikazu, et al.
Publicado: (2015)

X Chromosome Inactivation Timing is Not eXACT: Implications for Autism Spectrum Disorders
por: LaSalle, Janine M.
Publicado: (2022)

Erratum to: ‘Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism – the J-EINSTEIN DVT and PE program’
por: Yamada, Norikazu, et al.
Publicado: (2016)

Effect of Rivaroxaban and Clopidogrel Combination Therapy on In-Stent Responses After Everolimus-Eluting Stent Implantation in a Porcine Coronary Model
por: Kitano, Daisuke, et al.
Publicado: (2022)

XACT, a long non-coding transcript coating the active X chromosome in human pluripotent cells
por: Vallot, Céline, et al.
Publicado: (2013)

XACT Noncoding RNA Competes with XIST in the Control of X Chromosome Activity during Human Early Development
por: Vallot, Céline, et al.
Publicado: (2017)

A primate-specific retroviral enhancer wires the XACT lncRNA into the core pluripotency network in humans
por: Casanova, Miguel, et al.
Publicado: (2019)

Venous thromboembolism in patients with cancer: design and rationale of a multicentre, prospective registry (Cancer-VTE Registry)
por: Ohashi, Yasuo, et al.
Publicado: (2018)

Primary and secondary prevention of stroke and systemic embolism with rivaroxaban in patients with non-valvular atrial fibrillation: Sub-analysis of the EXPAND Study
por: Uchiyama, Shinichiro, et al.
Publicado: (2018)

Clinical Use of Rivaroxaban: Pharmacokinetic and Pharmacodynamic Rationale for Dosing Regimens in Different Indications
por: Trujillo, Toby, et al.
Publicado: (2014)

Ischemic stroke, hemorrhage, and mortality in patients with non-valvular atrial fibrillation and renal dysfunction treated with rivaroxaban: sub-analysis of the EXPAND study
por: Atarashi, Hirotsugu, et al.
Publicado: (2021)

Clinical risk factors of stroke and major bleeding in patients with non-valvular atrial fibrillation under rivaroxaban: the EXPAND Study sub-analysis
por: Sakuma, Ichiro, et al.
Publicado: (2019)

Spontaneous mesenteric hematoma of the sigmoid colon associated with rivaroxaban: A case report
por: Hirano, Katsuhisa, et al.
Publicado: (2018)

Erratum to: Clinical Use of Rivaroxaban: Pharmacokinetic and Pharmacodynamic Rationale for Dosing Regimens in Different Indications
por: Trujillo, Toby, et al.
Publicado: (2014)

Rivaroxaban versus Warfarin in Patients with Mechanical Heart Valve: Rationale and Design of the RIWA Study
por: Durães, André R., et al.
Publicado: (2018)

Correction to: Clinical risk factors of stroke and major bleeding in patients with non-valvular atrial fibrillation under rivaroxaban: the EXPAND Study sub-analysis
por: Sakuma, Ichiro, et al.
Publicado: (2019)

Evaluation of Perivascular Adhesion Formation in New Zealand White Rabbits Using Oxiplex and DuraSeal Xact Adhesion Barrier System
por: Mo, Fred, et al.
Publicado: (2009)

XACT-seq: A photocrosslinking-based technique for detection of the RNA polymerase active-center position relative to DNA in Escherichia coli
por: Pukhrambam, Chirangini, et al.
Publicado: (2021)

Clinical implication of monitoring rivaroxaban and apixaban by using anti-factor Xa assay in patients with non-valvular atrial fibrillation
por: Ikeda, Kozue, et al.
Publicado: (2016)

XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation
por: Camm, A John, et al.
Publicado: (2014)

Evidence-Based Development and Rationale for Once-Daily Rivaroxaban Dosing Regimens Across Multiple Indications
por: Kubitza, Dagmar, et al.
Publicado: (2016)

Rivaroxaban in patients with ischaemic chronic cardiomyopathy and obstructive peripheral arterial disease: rationale for treatment and results
por: Savonitto, Stefano, et al.
Publicado: (2020)

Rationale and Design of Rivaroxaban Estimation With Warfarin in Atrial Fibrillation Patients With Coronary Stent Implantation (REWRAPS)
por: Ozaki, Yukio, et al.
Publicado: (2022)

XactMice: humanizing mouse bone marrow enables microenvironment reconstitution in a patient-derived xenograft model of head and neck cancer
por: Morton, J. Jason, et al.
Publicado: (2015)

Novel Anticoagulant Therapy of Venous Thromboembolism: Current Status and Future Directions
por: Nakamura, Mashio, et al.
Publicado: (2017)

Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism in Japan
por: Nakamura, Mashio, et al.
Publicado: (2017)

Medically Ill hospitalized Patients for COVID-19 THrombosis Extended ProphyLaxis with rivaroxaban ThErapy: Rationale and Design of the MICHELLE Trial()
por: Ramacciotti, Eduardo, et al.
Publicado: (2021)

Rivaroxaban for the treatment of cerebral venous thrombosis
por: Esmaeili, Sara, et al.
Publicado: (2021)

Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial
por: Khorana, Alok A., et al.
Publicado: (2017)

Rationale and Design of the Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion Trial (CAPITAL-RAPTOR)
por: Di Santo, Pietro, et al.
Publicado: (2023)

XALIA: rationale and design of a non-interventional study of rivaroxaban compared with standard therapy for initial and long-term anticoagulation in deep vein thrombosis
por: Ageno, Walter, et al.
Publicado: (2014)

Rationale and design of XAMOS: noninterventional study of rivaroxaban for prophylaxis of venous thromboembolism after major hip and knee surgery
por: Turpie, Alexander GG, et al.
Publicado: (2012)

Rivaroxaban with Aspirin Versus Aspirin for Peripheral Arterial Disease and Intermittent Claudication. Rationale and Design of the COMPASS CLAUDICATION Trial
por: Ramacciotti, Eduardo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_21seu428bmr8m4tjkchrbf725a